Alemtuzumab Induction Is Associated With Equalization of Graft Outcomes Between Elderly and Nonelderly Kidney Transplant Recipients: A Single-Center Report.
CONCLUSIONS: Elderly age is not a predictor of rejection or death-censored graft loss in individuals who receive alemtuzumab induction. Despite elevated overall mortality, elderly recipients induced with alemtuzumab demonstrated rejection, graft, and short-term patient survival rates similar to younger recipients.
PMID: 31050614 [PubMed - as supplied by publisher]
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - Category: Transplant Surgery Authors: DeLeonibus A, Mitro G, Brooks J, Rees M, Ortiz J Tags: Exp Clin Transplant Source Type: research
More News: Bone Graft | Kidney Transplant | Kidney Transplantation | Middle East Health | Transplant Surgery | Transplants | Urology & Nephrology